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Objectives. Mechanisms underlying the morning increase in
platelet aggregation produced by arising and assuming the up-
right posture were studied by examining 1) the expression on the
platelet surface of activation-dependent markers; 2) platelet ag-
gregation in whole blood; and 3) hematologic factors likely to
inﬂuence aggregation.
Background. The morning increase in thrombotic cardiovascu-
lar events has been attributed, in part, to the morning surge in
platelet aggregability, but its mechanisms are poorly understood.
Methods. Expression of seven platelet surface antigens (includ-
ing P-selectin, activated GPIIb-IIIa and GPIb-IX), whole-blood
platelet aggregation, platelet count and hematocrit were measured
before and after arising in 17 normal volunteers. The ﬁbrinolytic
variables, tissue-type plasminogen activator, plasminogen activa-
tor inhibitor 1 and catecholamine levels were also measured.
Results. On arising and standing, platelet aggregation in-
creased by 71% (p < 0.01) and 27% (p < 0.03) in response to
collagen and adenosine diphosphate, respectively. However, there
was no change in any of the activation-dependent platelet surface
markers. Whole-blood platelet count and hematocrit increased by
15% and 7% (both p < 0.0001), respectively. Norepinephrine and
epinephrine levels increased by 189% (p < 0.0001) and 130% (p <
0.01), respectively. Tissue-type plasminogen activator antigen
increased (31%, p < 0.01), but there was no signiﬁcant increase in
plasminogen activator inhibitor 1, suggesting an overall increase
in ﬁbrinolysis on standing. Prothrombin fragment 1.2 increased
by 28% (p < 0.02), indicating a small increase in thrombin
generation. The increases in hematocrit and platelet count that
occurred on standing were carefully mimicked in vitro and
resulted in a 115% (p < 0.05) increase in platelet aggregation in
response to adenosine diphosphate.
Conclusions. These data demonstrate that the morning in-
crease in platelet aggregation is not accompanied by expression of
activation-dependent platelet surface receptors and suggest that
the increase in whole-blood aggregation may be primarily due to
the increases in catecholamine levels, platelet count and hemocon-
centration.
(J Am Coll Cardiol 1996;28:1789–95)
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Myocardial infarction, stroke and sudden death occur more
commonly in the morning than at other times (1–3). The
circadian variation in hemostatic factors that promote throm-
bus formation or discourage its dissolution is widely believed to
be responsible for this increased incidence of thrombotic
events. In the early morning hours there is a trough in
ﬁbrinolysis, and on subjects’ awakening and assuming the
upright posture (arising), most but not all investigators have
reported an increased tendency of platelets to aggregate in
platelet rich plasma (4–11). The mechanism for this increase in
aggregation has remained obscure; some investigators have
postulated that the catecholamine surge that accompanies
arising directly activates platelets; however, in vitro data
suggest that catecholamine levels on arising are insufﬁcient to
directly affect platelet aggregation (12–16).
The assessment of platelet activation by whole-blood ﬂow
cytometry is a recent development and is potentially a much
more speciﬁc and reproducible technique than traditional
aggregation studies (17). The technique depends on the detec-
tion of surface antigens (usually glycoproteins [GPs] or their
ligands) that become expressed during platelet activation.
Antibodies that detect surface expression of activated GPIIb-
IIIa, the alpha-granule membrane protein P-selectin or
surface-bound ligands, such as ﬁbrinogen or von Willebrand
factor (vWF), have been used in most studies. Recently, the
decrease in expression of GPIb-IX and the increase in expres-
sion of GPIV have been proposed as more sensitive markers of
platelet activation (18,19).
The present study was performed to investigate 1) whether
the increase in platelet aggregation on arising is accompanied
by expression on the platelet surface of markers of activation;
2) to determine whether the increase in aggregation occurs in
the more physiologic milieu of whole blood; 3) to delineate the
changes in hematologic factors on standing that can inﬂuence
platelet aggregation; and 4) to further examine the effects on
ﬁbrinolytic factors of standing.
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Methods
Subjects. Seventeen normal subjects (12 men, 5 women;
mean [SEM] age 33 2 years, range 23 to 51) were admitted
to hospital the day before the study. Subjects avoided aspirin
and other agents known to alter platelet function for 14 days
before the study and refrained from caffeine-containing bev-
erages the day before and during the study. A 16-gauge venous
cannula was inserted into a forearm vein, and saline was
continuously infused. Free-ﬂowing blood withdrawals were
conﬁrmed in each subject. No heparin was used. Subjects were
provided with a quiet, darkened room and slept undisturbed
until 7 AM, when a blood sample was obtained by the two-
syringe technique, and immediately afterward, blood pressure
and heart rate were recorded. A sphygmomanometer cuff at
30 mm Hg was used to assist with blood withdrawal. After
10 min, subjects arose and remained standing until a second
sample was obtained a mean of 26 4 min later. Samples were
analyzed for whole-blood ﬂow cytometry, impedance aggre-
gometry, platelet count and hematocrit. Plasma was assayed
for catecholamine, ﬁbrinogen, tissue-type plasminogen activa-
tor antigen (t-PA), plasminogen activator inhibitor antigen and
prothrombin fragment 1.2 levels. Written informed consent
was obtained from subjects, and the study was approved by the
Investigational Review Board of the National, Heart, Lung,
and Blood Institute.
Whole-blood ﬂow cytometry. The technique of whole-
blood ﬂow cytometry allows assessment of platelet activation
within minutes of sampling and avoids centrifugation or stir-
ring, which can cause ex vivo platelet activation. Samples were
taken into polypropylene syringes and immediately placed in
tubes containing 32% sodium citrate (diluted 99:1). Within
5 min, samples were diluted in modiﬁed HEPES–Tyrode’s
buffer. Ten 20-l aliquots were then each incubated with a
saturating concentration of one of nine monoclonal antibodies
(two directed at GPIb-IX; two at platelet-bound vWF; and one
each at platelet-bound ﬁbrinogen, activated GPIIb-IIIa, GPIV,
P-selectin and a lysosomal surface-expressed antigen) conju-
gated with ﬂuorescein isothiocyanate (FITC), a saturating
concentration of a biotinylated antibody (directed at com-
plex GPIIb-IIIa) to identify platelets and phycoerythrin–
streptavidin. The samples were analyzed within 2 h on an
EPICS 753 ﬂow cytometer (Coulter Corporation). Platelets
were identiﬁed by both phycoerythrin–streptavidin positivity
and characteristic light scatter. Platelet binding of monoclonal
antibodies was determined by analyzing both for the propor-
tion with ﬂuorescence (percent positivity) and intensity of
ﬂuorescence (arbitrary units). This latter measurement reﬂects
relative changes in the number of antigens expressed per
platelet.
Monoclonal antibodies directed against GPIb-IX (thrombin
site, colony 12.4), platelet-bound ﬁbrinogen (colony 26.8) and
vWF (colonies 22.9 and 30.7), a lysosomal surface-expressed
antigen (colony 32.9) and P-selectin (colony 12.2) were pro-
duced in the Hematology Service, Clinical Center, National
Institutes of Health (20–22). An antibody directed against
GPIb-IX (vWF site) was obtained from Pharminogen; the
antibody against activated GPIIb-IIIa (PAC-1) was provided
by Sanford J. Shattil, MD, University of Pennsylvania; GPIV
(OKM5) antibody was puchased from Ortho Diagnostic Sys-
tems, and GPIIb-IIIa complex antibody was obtained from
Immunotech.
Platelet aggregation. Aggregation was assessed with a mo-
bile four-channel impedance aggregometer (Chronolog-Log
Corporation), which allowed measurement of aggregation
beginning 1 min after blood sampling. Blood (2.25 ml) was
collected into preheated plastic syringes containing 0.25 ml of
sodium citrate (3.8%, pH 7.4). Samples were diluted 1:1 in
physiologic saline, stirred at 1,200 rpm and kept at 37C.
Aggregation was induced by adenosine diphosphate (ADP)
(ﬁnal concentration 2.5 to 20 mol/liter) and collagen (ﬁnal
concentration 1.0 to 3.0 g/ml). For each aggregating agent,
two aggregation curves were recorded. The aggregation curve
was recorded for 5 min and quantiﬁed by calculating the area
under the curve relating electrical impedance to time (Ohms.
seconds [.s]). This single measurement is sensitive to changes
in any of the standard aggregation curve variables: lag time
(time from addition of aggregating agent to onset of curve),
slope and maximal amplitude. On the day before the study,
aggregation curves to a range of concentrations of ADP and
collagen were obtained and used to determine the concentra-
tions required to achieve intermediate curves that would be
responsive to both increases and decreases in platelet aggre-
gation.
Hemostatic and ﬁbrinolytic factors. Platelet count and
hematocrit samples were collected in EDTA and analyzed by
standard clinical methods (Coulter counter model STKS).
Fibrinogen and prothrombin fragment 1.2 levels were deter-
mined in citrated plasma by a standard clinical photooptical
clot detection method and by enzyme immunoassay (Enzgnost
F12 micro, Behring Diagnostics Inc.), respectively. Samples
for determination of plasma t-PA and plasminogen activator
inhibitor 1 antigen levels were collected into tubes containing
sodium citrate, theophylline, adenosine and dipyridamole
(Diatube H, Diagnostica Stago, Asnieres-Sur-Seine, France)
and were determined by enzyme immunoassay (TintElize tPA,
Biopool and Asserachrom PAI-1, Diagnostica Stago). To allow
for the hemoconcentrating effect of standing, plasma concen-
trations of both rest and standing samples were converted to
whole-blood concentrations
Abbreviations and Acronyms
ADP  adenosine diphosphate
FITC  ﬂuorescein isothiocyanate
GP  glycoprotein
PPP  platelet-poor plasma
PRP  platelet-rich plasma
t-PA  tissue-type plasminogen activator
vWF  von Willebrand factor
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Whole blood Plasma 1Hematocrit,
and statistical comparisons were then repeated. Plasma epi-
nephrine and norepinephrine levels were determined by high
performance liquid chromatography, as previously described
(23).
In vitro studies. Nine in vitro aggregation studies were
performed on blood samples obtained from four normal
volunteers (two men), three of whom also participated in the in
vivo study. All blood samples were obtained from supine,
rested subjects in an identical manner to the in vivo study.
Citrated blood was serially centrifuged to obtain platelet-rich
plasma (PRP) (760 g for 3 min) and platelet-poor plasma
(PPP) (1,500 g for 10 min). Fresh whole blood was collected
for impedance aggregometry, but instead of dilution with
physiologic saline 1:1 (see above), it was diluted to obtain a
control and a hemoconcentrated sample. The hemoconcen-
trated sample was achieved by diluting whole blood with PRP
and saline (ratio 1.1:0.1:0.8, respectively) and the control
sample by dilution with PPP and saline (ratio 1:0.2:0.8).
Aggregation curves were started within 3 min of sampling.
Platelet count and hematocrit were measured in both samples.
Duplicate aggregation curves in response to ADP were ob-
tained for six control and six hemoconcentrated samples.
Collagen curves were obtained from three control and three
hemoconcentrated samples.
Statistical analysis. Mean values for duplicate aggregation
curves for each aggregating agent were obtained. The effects of
standing were compared by a paired Student t test. A p value
	0.05 (two-tailed test) was considered signiﬁcant for t tests of
the primary end points (platelet measurements) and p 	 0.01
for secondary end points (plasma factors). This approach also
allowed for the effects of multiple comparisons. The Pearson
coefﬁcient was used to test for correlations. Results are
expressed as mean value  SEM.
Results
Before arising, mean heart rate was 60  2 beats/min, and
this increased to 87  3 beats/min on standing. Rest epineph-
rine and norepinephrine levels increased on standing by 189%
(p 	 0.01) and 130% (p 	 0.001), respectively (Table 1).
Platelet aggregation (Fig. 1). In whole blood, ADP-
induced platelet aggregation increased markedly on arising
and standing in the morning. The area under the ADP
aggregation curve increased by 71% (p 	 0.01), and collagen-
induced aggregation increased by 27% (p 	 0.03).
Flow cytometry studies (Table 2). Nine activation-dependent
antibodies were studied in whole blood before and after arising.
Supine measurements demonstrated very low levels of expression
Figure 1. Effect of standing on whole-blood platelet aggregation in
response to ADP (top) and collagen (bottom). Circles and vertical
bars  mean values  SEM, respectively.




(mean  SEM) p Value
Catecholamines
Epinephrine (pg/ml) 14  2 33  6 	 0.01
Norepinephrine
(pg/ml)
177  17 512  50 	 0.001
Fibrinolytic factors
PAI-1 antigen (ng/ml) 11.4  3.4 13.8  4.8 0.03
t-PA antigen (ng/ml) 6.0  0.9 7.7  1.1 	 0.01
Procoagulant factors
Fibrinogen (mg/dl) 203  14 241  30 	 0.03
Fibrinogen
(whole blood)*
117  7 133  16 0.02
PT fragment 1.2
(nmol/liter)
0.69  0.11 0.86  0.12 0.01
*Calculated whole-blood concentration. PAI  plasminogen activator inhib-
itor; PT  prothrombin; t-PA  tissue-type plasminogen activator.
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(mean positivity, all 1.2%) of antibodies directed against
P-selectin, activated GPIIb-IIIa, vWF and ﬁbrinogen, indicating
that no signiﬁcant ex vivo activation occurred as a result of our
methodology. On standing, the expression of these markers did
not change (mean positivity, all 1.1%). Furthermore, the inten-
sity of ﬂuorescence of antibodies against GPIb-IX receptors did
not decrease and that against GPIV receptors did not increase on
arising.
Hemostatic factor levels (Fig. 2, Table 1). Increases in
platelet count and hematocrit, which can promote both whole-
blood and PRP aggregation, accompanied standing. On aris-
ing, platelet count increased by 15  3% and hematocrit by
7 1% (both p	 0.001). There was a trend toward an increase
in plasma ﬁbrinogen levels that became nonsigniﬁcant when
allowance was made for changes in hematocrit (12  7%,
p 
 0.2). Prothrombin fragment 1.2, a marker of thrombin
generation, increased by 28  6% and remained signiﬁcant
after adjustment for changes in hematocrit (22  6%, p 	
0.01).
Fibrinolytic factor levels (Table 1). The t-PA factor anti-
gen levels increased on arising (31  7%), even after adjust-
ment for changes in hematocrit (25  7%, p 	 0.01). Plasmin-
ogen activator inhibitor antigen levels did not change
signiﬁcantly (p  0.3).
In vitro aggregation studies. To mimic the effect of stand-
ing on platelet count and hematocrit, rest whole-blood samples
were enriched with PRP, and dilution with saline was reduced
before induction of aggregation. This process increased plate-
let count and hematocrit by 17  2% and 10  1%, respec-
tively. Aggregation in response to ADP increased from 104 
27 .s in the control sample to 224  48 .s in the hemocon-
centrated and platelet-enriched sample (115%, p 	 0.01). In
response to collagen, aggregation increased from 86  14 to
222  4 .s, respectively. Duplicate ADP aggregation curves
for six samples from the same subject, each with different red
cell and platelet concentrations, demonstrated strong correla-
tions between increasing platelet count and aggregation (y 
4.3x  873, r  0.879, p 	 0.03) and between hematocrit and
aggregation (y  22x  855, r  0.68, p  0.14). Similarly,
collagen aggregation curves for four samples from another
subject demonstrated strong correlations with both platelet
count (y  4.0x  762, r  0.93) and hematocrit (y  33x 
1,222, r  0.97).
Discussion
The present study clariﬁes several aspects of the effects on
platelet aggregation of arising and assuming the upright pos-
ture in the morning: 1) On arising, increased platelet aggrega-
tion can readily be observed in whole blood; 2) this increased
aggregation is not accompanied by platelet activation, as
evidenced by changes in activation-dependent markers on the
platelet surface; 3) the observed increase in aggregation in
whole blood may be partly explained by increases in platelet
count and hematocrit that accompany arising. In addition, the
study conﬁrmed previous reports of increased ﬁbrinolysis on
standing and provided new evidence of an opposing increase in
thrombin generation on standing.
Comparison with previous studies. Studies reporting the
effects of arising in the morning on platelet aggregation
(7–11,13) have exclusively studied aggregation in PRP, and to
our knowledge, the present study is the ﬁrst to report the
effects of arising on platelet aggregation in whole blood. Of the
previous studies on PRP, the majority have reported a signif-
icant increase in aggregation with standing, but interestingly,
the only study that adjusted for the increase in platelet count
on standing reported nonsigniﬁcant results (11).
In whole blood, an increase in platelet count promotes the
platelet release reaction, and a large increase in hematocrit
promotes platelet aggregation (24–26). Furthermore, in PRP,
exercise-induced increases in aggregation may be explained by
increases in platelet count alone (27). Because we observed
signiﬁcant increases in platelet count and hematocrit on stand-
ing, we investigated the effects of this phenomenon on whole-
blood platelet aggregation in vitro. When these postural effects
of standing on platelet count and hematocrit were carefully
mimicked in vitro, whole-blood aggregation increased to a
similar extent as that observed in vivo when arising. Further-
more, for samples from the same subject, in vitro increases in
platelet count and to lesser extent hematocrit correlated
strongly with increases in aggregation. Thus, an increase in
platelet count and hematocrit with assumption of the upright
Table 2. Whole-Blood Flow Cytometry
Membrane Antigen
% Positive Intensity (arbitrary units)
Supine Standing Supine Standing
GPIb-IX (vWF) 98  1 98  1 132  3 132  2
GPIb-IX (thrombin) 97  1 97  0 103  5 103  5
GPIV 97  1 97  1 121  41 119  4
Activated GPIIb-IIIa 0.2  0.1 0.2  0.1 57  11 68  18
Fibrinogen 0.0  0.0 0.1  0.0 62  9 74  10
P-selectin 0.1  0.0 0.2  0.1 47  7 46  5
vWF (colony 22.9) 0.2  0.1 0.3  0.1 56  7 59  14
vVF (colony 30.7) 0.1  0.1 0.2  0.0 54  11 58  9
Lysosomal protein 1.2  0.5 1.1  0.5 37  7 40  7
Data presented are mean value  SEM. GP  glycoprotein; vWF  von Willebrand factor.
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posture may provide at least a partial explanation for our
apparently paradoxic observation of increased aggregation in
the absence of platelet activation.
The effect of standing on whole-blood platelet count and
hematocrit is believed to be due in part to increased epineph-
rine levels (10). Epinephrine infusions and exercise cause a
rapid but transient increase in platelet count and, importantly,
in platelet size (27–33). The spleen is the likely source of these
platelets because it is the only organ that contains sufﬁcient
sequestrated platelets (30% of the normal circulating pool)
of the right size (splenic platelets are larger than their circu-
lating counterparts) that could be rapidly released into the
circulation (34,35). Given the increase in catecholamine levels
that accompany standing and because larger platelets are
known to aggregate more readily, it is likely that the increase
in platelet count observed on standing is a result of the splenic
release of larger, more aggregable platelets (35,36).
Previous investigators have postulated that the morning
increase in aggregation is due to direct stimulation by epineph-
rine of platelet alpha2-receptors. However, the lowest reported
threshold for potentiation by epinephrine of ADP aggregation
is 600 pg/ml (approximately sevenfold higher than the highest
level recorded in our study), and the majority of studies have
reported thresholds of at least 1,800 pg/ml (12–15). One could
postulate that the increase in thrombin generation (see below)
combined with the increase in epinephrine could have contrib-
uted to the observed morning increase in aggregation. How-
ever in a study in which thrombin generation was increased
fourfold, no change in the epinephrine threshold was observed
(12).
Strenuous exercise in sedentary subjects has been reported
(19) to cause platelet activation, as measured by a ﬂow
cytometric method. Kestin et al. (19) reported downregulation
of GPIb-IX after exercise, but the most consistent effect of
exercise was the sensitization of platelets to activation by
thrombin. In another ﬂow cytometric study (37), infusion of
high physiologic concentrations of epinephrine in normal
subjects sensitized platelets to activation by ADP when as-
sessed by ﬁbrinogen binding and P-selectin expression. How-
ever, epinephrine did not affect either of these markers of
activation in the absence of ADP. These studies are consistent
with the present one, and together they suggest that in vivo
physiologic increases in epinephrine do not directly activate
platelets but can sensitize platelets to the action of aggregating
agents.
Advantages of whole blood-platelet aggregometry and ﬂow
cytometry. The technique of whole-blood impedance aggre-
gometry has been demonstrated (38) to correlate with PRP
optical aggregometry in a large population-based study. Fur-
thermore, characteristic features of speciﬁc aggregating agents,
such as the lag time between addition of collagen and onset of
aggregation, are seen with both techniques (39–41), which
suggests that impedance aggregometry is indeed a measure of
platelet aggregability and provides information similar to that
of traditional turbidometry (39–42). Impedance aggregometry
has the advantage of being a whole-blood technique, and it can
be performed immediately after blood sampling, thus avoiding
the spontaneous activation of platelets that can occur with time
in citrated blood. The technique also avoids both the activation
of platelets and the loss of subpopulations of platelets that can
occur during the preparation of platelet rich plasma.
In addition to the aforementioned advantages of the whole
blood-technique, ﬂow cytometric platelet analysis provides
direct measurement of platelet activation by analyzing GP
changes on the platelet surface. In samples that have not been
stimulated ex vivo with aggregating agents, ﬂow cytometric
platelet analysis is unaffected by variables, such as platelet
count, size and density. The technique is very sensitive and can
detect populations of activated platelets as small as 1% of all
platelets in the sample (9). In pilot experiments (data not
Figure 2. Effect of standing on platelet count (top) and hematocrit
(bottom). Symbols as in Figure 1.
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shown), we conﬁrmed the recent reports demonstrating that a
decrease in intensity of ﬂuorescence of antibody to GPIb-IX
may be used as a marker of platelet activation (18).
In our study, platelet aggregation, ﬂow cytometry, platelet
count, hematocrit and all plasma factors were measured on the
same blood samples from subjects before and after arising in
the morning. In particular, aggregation and ﬂow cytometric
studies used the same anticoagulant (sodium citrate), and both
studies were initiated within 5 min of blood sampling. Flow
cytometric analysis was performed promptly after adding the
platelet antibodies, thus obviating the need for ﬁxing agents.
The low levels of expression of activation-dependent platelet
markers at baseline, compared with most whole-blood ﬂow
cytometric platelet studies (18,19,37), clearly suggest that
minimal ex vivo activation did occur with our technique. We
studied a comprehensive array of surface markers of activa-
tion, including two recently reported markers (changes in
antibody ﬂuorescence intensity of GPIb-XI and GPIV)
(18,19). Despite these efforts, on the same blood samples that
showed marked increases in whole-blood impedance aggre-
gometry on standing, there was no suggestion of any activation-
dependent changes in platelet surface markers.
Postural changes in ﬁbrinolysis and thrombin generation.
A circadian rhythm in ﬁbrinolysis with a trough in the early
morning has long been recognized (4,5). A recent study (43)
demonstrated that standing increases ﬁbrinolysis, but because
this effect was consistent throughout the day, it did not affect
the underlying circadian rhythm. The results of the present
study suggest that the increase in ﬁbrinolysis on standing is at
least partly explained by an increase in t-PA in the absence of
an increase in plasminogen activator inhibitor. These results
are in agreement with those of Winther et al. (10).
Prothrombin fragment 1.2 levels increased on standing even
after allowing for the increase in hematocrit. Prothrombin
fragment 1.2 is cleaved from prothrombin when thrombin is
generated by the action of factors Xa and Va. In conditions
such as disseminated intravascular coagulation, values equal to
10 times the upper limit of normal are seen, whereas in venous
thromboembolism, 2-fold increases typically occur (44,45).
Mild elevations of prothrombin fragment 1.2 levels have been
associated with hypertension, male gender, smoking and in-
creasing age, all of which are risk factors for atherosclerosis
(46,47). Thus, our ﬁnding of a modest increase in prothrombin
fragment 1.2 levels with standing suggest that thrombin gener-
ation occurs on standing and adds a further factor that
contributes to the prothrombotic state associated with arising.
However, until the risk of arterial thrombosis associated with
such small increases in prothrombin fragment 1.2 has been
deﬁned, the relevance of our ﬁnding remains unclear.
Conclusions. Platelet aggregation in whole blood increases
on arising in the morning, but this increase is not associated
with evidence of platelet activation as detected by changes in
expression of activation-dependent platelet surface markers.
Increases in platelet count, hematocrit and catecholamine
levels that accompany assumption of the upright posture may
be primarily responsible for the observed effects.
We acknowledge the organizational assistance of Donna-Jo Mayo, RN.
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